Galera's Small-Molecule Shields to Protect Against Superoxide
By Jennifer Boggs
Friday, December 28, 2012
Galera Therapeutics Inc., a 2009 start-up based on the approach of treating disease by targeting superoxide, came out of stealth mode in December with a new CEO and a Series A financing of $11 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.